Nadir Prostat Kanserleri
Özet
Prostat kanserlerinin %95'ten fazlasını adenokarsinomlar oluştururken, geri kalan küçük bir bölümünü nöroendokrin tümörler, bazal hücreli karsinom, skuamöz hücreli karsinom, adenoskuamöz karsinom, primer prostat sarkomları ve primer prostat lenfomaları gibi nadir alt tipler meydana getirmektedir. Bu nadir maligniteler, geleneksel adenokarsinomların aksine sıklıkla normal serum prostat spesifik antijen (PSA) düzeyleri ile seyrederek klinik tanı süreçlerini zorlaştırmaktadır. Küçük ve büyük hücreli nöroendokrin karsinomlar ile primer sarkomlar, agresif klinik seyirleri, erken yaşta görülme eğilimleri ve viseral organ metastazları ile öne çıkarken; skuamöz alt tipler hormonal tedavilere direnç göstermektedir. Sınırlı vaka sayıları nedeniyle bu heterojen kanser grupları için randomize kontrollü klinik çalışmalar yetersizdir ve standart tedavi kılavuzları mevcut değildir. Tedavinin temel köşe taşını, uzak metastazı olmayan erken evre olgularda cerrahi rezeksiyon ve radikal prostatektomi oluşturmaktadır. Saldırgan küçük hücreli nöroendokrin tümörlerde platin bazlı sistemik kemoterapiler tercih edilirken, primer prostat lenfomalarında CHOP rejimi ile yüksek oranlarda tam yanıt ve remisyon elde edilebilmektedir. Bu nedenle, nadir prostat kanseri olgularının doğru histopatolojik tanısı sonrasında, deneyimli merkezlerde multidisipliner ve bireyselleştirilmiş tedavi stratejilerinin planlanması klinik sağkalımı optimize etmek adına kritik bir öneme sahiptir.
While adenocarcinomas constitute more than 95% of all prostate cancers, the remaining small fraction consists of rare subtypes including neuroendocrine tumors, basal cell carcinoma, squamous cell carcinoma, adenosquamous carcinoma, primary prostate sarcomas, and primary prostate lymphomas. Unlike typical adenocarcinomas, these rare malignancies frequently present with normal serum prostate-specific antigen (PSA) levels, which significantly complicates the clinical diagnosis. Small cell and large cell neuroendocrine carcinomas, along with primary sarcomas, are characterized by highly aggressive clinical courses, a propensity for visceral metastases, and occurrence in relatively younger patients, whereas squamous subtypes exhibit resistance to conventional hormonal therapies. Due to the scarcity of documented cases, randomized controlled trials are lacking, and no standardized treatment guidelines exist for these heterogeneous groups. Surgical resection remains the primary cornerstone of management for early-stage diseases without distant metastasis. Aggressive neuroendocrine carcinomas are typically managed with platinum-based systemic chemotherapy, while primary lymphomas respond favorably to the CHOP regimen, demonstrating high complete remission rates. Consequently, achieving an accurate documentation of histopathological diagnosis and managing patients through a multidisciplinary, individualized approach at experienced centers is critical for optimizing clinical survival outcomes.
Referanslar
Sung, H, Ferlay, J, Siegel, RL, Laversanne, M, Soerjomataram, I, Jemal, A, Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality world wide for 36 cancers in 185 countries. CA Cancer J Clin. 2021: 71: 209- 249. https://doi.org/10.3322/caac.21660.
Elabbady A, Kotb AF. Unusual presentations of prostate cancer: A review and case reports. Arab J Urol. 2013 Mar;11(1):48-53. doi: 10.1016/j.aju.2012.10.002. Epub 2012 Dec 6. PMID: 26579245; PMCID: PMC4442930.
Uptodate (2022). Clinical presentation and diagnosis of prostate cancer. 24.08.2022 tarihinde https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-prostate-cancer adresinden ulaşılmıştır.
Uptodate (2022). Interpretation of prostate biopsy. 24.08.2022 tarihinde https://www.uptodate.com/contents/interpretation-of-prostate-biopsy adresinden ulaşılmıştır.
Bolla M, Poppel HV. Prostat Kanseri Yönetimi. (Ahmet Bilici, Çev. Ed.). İstanbul: EmaTıp Kitabevi;2021.
Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999; 6:503.
Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol. 1996 Jul;27(7):683-7. doi: 10.1016/s0046-8177(96)90398-6. PMID: 8698312.
Reyes A, Moran CA. Low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate. Arch Pathol Lab Med 2004; 128:e166.
Parimi V, Goyal R, Poropatich K, Yang XJ. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol. 2014 Dec 9;2(4):273-85. PMID: 25606573; PMCID: PMC4297323.
WHO Classification of Tumours of the Urinary System and Mail Genital Organs, 4th ed, Moch H, Humphrey PA, Ulbright TM, Reuter VE (Eds), WHO, Lyon 2016.
Chang K, Dai B, Kong Y, et al: Basal cell carcinoma of the prostate: Clinicopathologic analysis of three cases and a review of the literature. World J SurgOncol11:193, 2013.
Ali TZ, Epstein JI. Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am J Surg Pathol. 2007 May;31(5):697-705. doi: 10.1097/01.pas.0000213395.42075.86. PMID: 17460452.
Grossman JE, Wu Y, Ye H, Bhatt RS. Case of Basal Cell Carcinoma of the Prostate Successfully Treated Before and After a BRCA2 Reversion Mutation. JCO PrecisOncol. 2018 Nov 16;2:PO.18.00193. doi: 10.1200/PO.18.00193. PMID: 32914001; PMCID: PMC7446519.
Ayyathurai R, Civantos F, Soloway MS, Manoharan M. Basalcellcarcinoma of theprostate: currentconcepts. BJU Int. 2007 Jun;99(6):1345-9. doi: 10.1111/j.1464-410X.2007.06857.x. Epub 2007 Apr 5. PMID: 17419700.
Koochekpour S: Androgenreceptorsignalingandmutations in prostatecancer. Asian J Androl 2010, 12:639–657.
Segawa N, Tsuji M, Nishida T, Takahara K, Azuma H, Katsuoka Y: Basalcellcarcinoma of theprostate: report of a caseandreview of thepublishedreports. Int J Urol 2008, 15:557–559.
Malik RD, Dakwar G, Hardee ME, Sanfilippo NJ, Rosenkrantz AB, Taneja SS. Squamouscellcarcinoma of theprostate. RevUrol. 2011;13(1):56-60. PMID: 21826130; PMCID: PMC3151589.
Munoz F, Franco P, Ciammella P, Clerico M, Giudici M, Filippi AR, Ricardi U. Squamouscellcarcinoma of theprostate: long-termsurvivalaftercombinedchemo-radiation. RadiatOncol. 2007 Apr 3;2:15. doi: 10.1186/1748-717X-2-15. PMID: 17407588; PMCID: PMC1852111.
Moskovitz B, Munichor M, Bolkier M, Livne PM: Squamouscellcarcinoma of theprostate. UrolInt 1993, 51:181-183.
Brunnhoelzl D, Wang J. Clinicalfeatures, treatment, prognosis, andoutcome of 47 patientswithpuresquamouscellcarcinoma of theprostate. Journal of ClinicalOncology 36, no. 6_suppl (February 20, 2018). DOI: 10.1200/JCO.2018.36.6.
Thompson GJ, Albers DD, Broders AC. Unusualcarcinomasinvolvingtheprostategland. J Urol. 1953;69:416-425.
Gray GF Jr, Marshall VF. Squamouscarcinoma of theprostate. J Urol. 1975;113:736-738.
Sieracki JC. Epidermoid carcinoma of the human prostate, report of three cases. LabInvest. 1955;4:232-240.
Moyana TN: Adenosquamouscarcinoma of theprostate. Am J SurgPathol 1987, 11:403-407.
Wang J, Wang FW, Lagrange CA, Hemstreet GP. Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate. RareTumors. 2010 Sep 30;2(3):e47. doi: 10.4081/rt.2010.e47. PMID: 21139962; PMCID: PMC2994527.
Parwani AV, Kronz JD, Genega EM, et al. Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am J SurgPathol. 2004;28:651–7.
Singh J, Sarkar K, Vijay M et al. AdenosquamousCarcinoma of theProstate: A RareAggressiveTumorwith a Review of theLiterature. UroTodayInt J. 2013 February;6(1):art 3. http://dx.doi.org/10.3834/uij.1944-5784.2013.02.03.
Ishigooka M, Yaguchi H, Tomaru M, et al. Mixed prostatic carcinoma containing malignant squamous element. Reports of twocases. Scand J UrolNephrol. 1994;28:425–7.
Accetta PA, Gardner WA.,JrAdenosquamouscarcinoma of prostate. Urology. 1983;22:73–5.
Randolph TL, Amin MB, Ro JY, Ayala AG. Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. ModPathol. 1997;10:612–29.
Hennessey A, Buller D, Sama S et al.Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy, Urology Case Reports, Volume 29,2020,101084, ISSN 2214-4420, https://doi.org/10.1016/j.eucr.2019.101084.
Wang X, Liu L, Tang H, Rao Z, Zhan W, Li X, Zeng H, Zhang P, Wei B, Lin T, Wei Q, Lu Y, Li X. Twenty-five cases of adult prostate sarcoma treated at a high-volume institution from 1989 to 2009. Urology. 2013 Jul;82(1):160-5. doi:10.1016/j.urology.2013.01.034. Epub 2013 Apr 16. PMID: 23601444.
Ding B, Zhang Y, Hu W, Hu D, Liu J, Zhao S, Wang F, Xue L, Xu Z, Chen L. Adult primary prostate sarcoma: A multi-center cohort study and comparison between Chinese and American cases. Asian J Surg. 2021 Jan;44(1):247-253. doi: 10.1016/j.asjsur.2020.06.004. Epub 2020 Jul 4. PMID: 32636119.
Musser JE, Assel M, Mashni JW, Sjoberg DD, Russo P. Adult prostate sarcoma: the Memorial Sloan Kettering experience. Urology. 2014 Sep;84(3):624-8. doi: 10.1016/j.urology.2014.05.036. PMID: 25168544; PMCID: PMC4678959.
Ball MW, Sundi D, Reese AC, et al. Multimodal therapy in the treatment of prostate sarcoma: the johns hopkins experience. Clin Genitourin Canc. 2015;13(5):435e440. https://doi.org/10.1016/j.clgc.2015.04.011.
De Bari B, Stish B, Ball MW, et al. Adult prostatic sarcoma: a contemporary multicenter Rare Cancer Network study. Prostate. 2017;77(10):1160e1166. https://doi.org/10.1002/pros.23375.
Sarris A, Dimopoulos M, Pugh W, et al. Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. J Urol. 1995;153:1852–4.
Ren, M., Liu, Y. Primary diffuse large B-cell lymphoma of the prostate: a case report and review of the literature. J Med Case Reports 15, 546 (2021). https://doi.org/10.1186/s13256-021-03143-3.
Bostwick DG, Iczkowski KA, Amin MB, et al. Malignant lymphoma involving the prostate: report of 62 cases. Cancer. 1998;83:732–8.
Görgel SN, Şefik E, Olğunelma V, Şahin E, Balcı U, Çallı AO. Primary non-Hodgkin follicular lymphoma of the prostate: A case report. Turk J Urol. 2014 Mar;40(1):57-8. doi: 10.5152/tud.2014.68466. PMID: 26328148; PMCID: PMC4548646.
Petrakis G, Koletsa T, Karavasilis V, Rallis G, Bobos M, Karkavelas G, Kostopoulos I. Primary prostatic lymphoma with components of both diffuse large B-cell lymphoma (DLBCL) and MALT lymphoma. Hippokratia. 2012 Jan;16(1):86-9. PMID: 23930067; PMCID: PMC3738403.
Fukutani K, Koyama Y, Fujimori M, Ishida T. Primary malignant lymphoma of the prostate: report of a case achieving complete response to combination chemotherapy and review of 22 Japanese cases. Nippon Hinyokika Gakkai Zasshi. 2003; 94: 621-625.
Csomor J, Kaszás I, Kollár B, Pajor L, Egyházi Z, Fekete S, et al. Prolonged survival using anti-CD20 combined chemotherapy in primary prostatic intravascular large B-cell lymphoma. Pathol Oncol Res. 2008; 14: 281-284.
